Faculty Collaboration Database

Concomitant adjuvant chemotherapy and radiotherapy for high risk breast cancer patients. Breast Cancer Res Treat 1991;17(3):171-7

Date

01/01/1991

Pubmed ID

2039839

DOI

10.1007/BF01806366

Scopus ID

2-s2.0-0025613575 (requires institutional sign-in at Scopus site)   1 Citation

Abstract

Thirty four patients treated with mastectomy and axillary node dissection for potentially curable breast cancer received a seven month combined adjuvant chemotherapy and radiation therapy program. These patients were considered to be at high risk for recurrence because they had either three or more positive axillary lymph nodes or their primary tumor was greater than 5 cm in diameter. The chemotherapy given at 3-week intervals consisted of cyclophosphamide, 600 mg/m2, Adriamycin 40 mg/m2, and methotrexate 40 mg/m2 during cycles 1 through 3 and 7 through 9. Radiation therapy was administered during cycles 4 through 6 with concomitant administration of 5-fluorouracil 600 mg/m2, vincristine 1.4 mg/m2, and prednisone 40 mg/m2 for 7 days. Median follow up time from initiation of study is 60 months (range 36-93). Seventeen of 34 patients (50%) remain free of recurrent breast cancer. Distant metastases and local-regional recurrence have occurred in 16 (47%) and 4 (12%) patients, respectively. Significant myelosuppression and infections requiring hospitalization were seen in 4 patients, with 1 treatment-related death. Adriamycin-containing chemotherapy and post-operative radiotherapy can thus be combined in an adjuvant treatment program with acceptable toxicity.

Author List

Hansen R, Erickson B, Komaki R, Janjan N, Cox J, Wilson JF, Anderson T

Author

Beth A. Erickson MD Professor in the Radiation Oncology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Combined Modality Therapy
Female
Humans
Middle Aged
Pilot Projects
Risk Factors